Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
InsuTab
- Development stage
- Preclinical
- Lead developer
- Insu Therapeutics
- Modality
- Peptides
- Administration
- Buccal
01
Overview
InsuTab is an investigational buccal insulin formulation developed by Insu Therapeutics, a spin-off of the University of British Columbia (UBC). It is designed to deliver insulin through the lining of the mouth (buccal mucosa) using a mucoadhesive, layered dosage-form architecture with a unidirectional release mechanism. This needle-free alternative to injectable insulin is intended for the treatment of diabetes (Type 1 and Type 2) and does not require fasting or food/drink restrictions around dosing.
- Brand names
- InsuTab
- Other names
- Insu buccal insulin tabletbuccal insulin
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on InsuTab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InsuTab.